Multi-omics characterization of response to PD-1 inhibitors in advanced melanoma

ABSTRACT: Immunotherapy improves the survival of patients with advanced melanoma, 40% of whom become long-term responders. However, not all patients respond to immunotherapy. Further knowledge about the processes involved in response and resistance to immunotherapy is still needed. In this study, clinical paraffin samples from fifty-two advanced melanoma patients treated with anti-PD1 inhibitors were assessed by high-throughput proteomics and RNA-seq. The obtained proteomics and transcriptomics data were analyzed using network analyses based on probabilistic graphical models to identify those biological processes involved in response to immunotherapy. Additionally, proteins related to overall survival were studied.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Skin

DISEASE(S): Melanoma

SUBMITTER: Antje Dittmann  

LAB HEAD: Enrique Espinosa

PROVIDER: PXD038155 | Pride | 2023-09-25

REPOSITORIES: Pride